GLP-1RAs Linked to Reduced Uveitis Risk - Top-Institutions - MDSpire

GLP-1RAs Linked to Reduced Uveitis Risk

A large cohort study suggests uveitis risk is lower in patients taking GLP-1 receptor agonists, compared to other antihyperglycemic drugs.

  • By

  • Jim Gallagher, senior managing editor

  • September 1, 2025

  • 3 min

Share

Top Institutions in Ophthalmology

Brief introduction explaining scope and methodology.

  • #1

    Cleveland Clinic Cole Eye Institute
    Cleveland Clinic Cole Eye Institute

    Cleveland, OH

    Key Differentiators

    • Ophthalmology
    • Endocrinology
    • Clinical Research

  • #2

    Massachusetts Eye and Ear Infirmary, Harvard Medical School
    Massachusetts Eye and Ear Infirmary, Harvard Medical School

    Boston, MA

    Key Differentiators

    • Ophthalmology
    • Immunology
    • Clinical Trials

  • #3

    Johns Hopkins Wilmer Eye Institute
    Johns Hopkins Wilmer Eye Institute

    Baltimore, MD

    Key Differentiators

    • Ophthalmology
    • Inflammation Research
    • Endocrinology

  • #4

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Ophthalmology
    • Endocrinology
    • Translational Medicine

  • #5

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Ophthalmology
    • Endocrinology
    • Clinical Epidemiology

Original Source(s)

GLP-1RAs Linked to Reduced Uveitis Risk

  • by Jim Gallagher, senior managing editor

  • September 1, 2025

Related Content

New Target for Uveitis Therapy

Could targeting cGAS-STING represent a new treatment avenue for uveitis?

  • May 21, 2026

  • 3 min
Ocular Toxoplasmosis Review

Sleep, stress, and pregnancy emerge as potential drivers of ocular toxoplasmosis recurrence in recent retrospective study

  • July 15, 2026

  • 4 min
Treatment Strategies in Endogenous Fungal Endophthalmitis

Management of endogenous fungal endophthalmitis is complex, with wide variation in treatment strategies. Systemic markers of disease appear to influence the choice of initial therapy more than ocular findings. Although no definitive evidence favors IV over oral systemic therapy, a comprehensive, multidisciplinary approach that considers ocular involvement is essential to optimize patient outcomes in EFE.